How the genomics health revolution is failing ethnic minorities

December 8, 2017

Canada is one of the most ethnically diverse nations in the world. However, this diversity is largely missing from our growing collections of genomic data. Because genomic information is increasingly used in health care, what does this mean for our ethnic minorities, including Indigenous Canadians?

Read More

World’s largest autism genome databank adds more than 2,000 sequences

November 3, 2017

The Autism Speaks MSSNG team announced the upload of an additional 2,030 fully sequenced genomes to the project’s cloud-based databank – making it the world’s largest whole genome resource for autism research. The MSSNG team includes Dr. Stephen Scherer and the Hospital for Sick Children (SickKids) in Toronto, Autism Speaks and Verily (formerly Google Life Sciences).

Read More

New test for BRCA1 and BRCA2 mutations could reduce pre-emptive mastectomies

October 25, 2017

A genetic test that more accurately predicts the risk of developing breast cancer could soon be used on high-risk groups. Researchers behind the test, available in England only at this time, say it could reduce the number of women choosing pre-emptive mastectomy surgery. The blood test looks at 18 genetic variations, or single-nucleotide polymorphisms (SNPs), known to affect the chances of getting breast cancer.

Read More

GA4GH to collaborate with 15 international genomic medicine initiatives

October 23, 2017

Advances in precision medicine depend on the ability to share genomic information voluntarily, securely and responsibly. To achieve this, The Global Alliance for Genomics and Health (GA4GH) has struck formal collaborations with 15 international genomic data initiatives. Ontario and Canada lead or help drive at least three of these, CanDIG, ICGC-ARGO and Matchmaker Exchange. Genome Canada has also announced new operational funding for the GA4GH.

Read More

Gene silencing drug opens new era for rare genetic disease treatments

October 11, 2017

Alnylam Pharmaceuticals Inc. unveiled positive results from a late-stage clinical trial of the drug patisiran for the treatment of familial amyloidotic polyneuropathy. Patisiran works by interrupting the production of a specific disease-causing protein through a process called RNA interference (RNAi), which eliminates unwanted proteins. Because RNAi can be easily tuned (in theory) to any disease, this may herald a new class of medicines.

Read More

AI startup Deep Genomics raises US$13M

October 10, 2017

The founding principle of Toronto-based Deep Genomics is “that the future of medicine will rely on artificial intelligence (AI), because biology is too complex for humans to understand.” After success at the startup assistance program run by University of Toronto’s Creative Destruction Lab, Deep Genomics has now closed a Series A financing deal that will allow it apply AI to search across 69 billion molecules to identify 1000 potential drugs.

Read More